Gapping up
In reaction to earnings/guidance:
- ANGO +13.5%, SKIL +11.2%, CXM +9.3%, RGP +5.6%, SLP +4.9%, CZOO +4.9%, APOG +3.3%, LEVI +2.5%, STZ +1.8%
Other news:
- MNTS +41.7% (signed multiple launch agreements with Space Exploration Technologies Corp)
- HPQ +13.5% (Berkshire Hathaway's Warren Buffett disclosed the purchase of ~11.1 mln shares worth nearly $400 mln)
- SPRO +9.6% (announces publication in NEJM for its Phase 3 ADAPT-PO clinical trial)
- NETI +6.2% (exec recently purchased 40000 shares)
- CIXX +5.7% (intends to take its U.S. Wealth Business public)
- GENI +5.4% (Sportico details NFL as largest US shareholder in GENI)
- GFL +4.5% (raises quarterly dividend by 10%)
- RLGT +4.4% (expects to report another record quarter in MarQ)
- FLGC +3.8% (Flora Growth's JustCBD has signed a deal with airport distribution juggernaut OTG Management to sell their CBD products in airports)
- XPOF +2.9% (prices offering of 4.5 mln shares of common stock at $20.00 per share)
- DOMO +2.7% (announces new integrations with Microsoft 365 and Teams)
- RNW +2.4% (announces investment by Mitsui in round-the-clock project)
- ADVM +2.3% (receives feedback from the FDA; to proceed with IND amendment process for ADVM-022 in wet AMD)
- KEYS +2.3% (announces collaboration with Luxshare-Tech re 800GB environments)
- SENS +2.2% (first US patient implanted with Eversense E3 CGM System)
- NTRA +1.7% (publishes VALID study results for prospera lung dd-cfDNA transplant rejection assessment test)
- GRPN +1.6% (10% owner (Pale Fire's Jan Barta) disclosed the purchase of ~375K shares worth ~$7.5 mln)
- ALKS +1.6% (Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society)
- COF +1.4% (authorizes repurchase of up to an additional $5 bln of common shares)
- COST +1% (reports adjusted March comps of +12.2%)
Analyst comments:
- ZETA +3.6% (upgraded to Outperform from Perform at Oppenheimer)
- BRY +2.9% (upgraded to Overweight from Neutral at Piper Sandler)
- AVO +2.6% (upgraded to Buy from Neutral at Citigroup)
- CDEV +2.4% (upgraded to Overweight from Neutral at Piper Sandler)
- COUP +2.3% (upgraded to Outperform from In-line at Evercore ISI)